about
Headache in essential thrombocythaemiaStructure-Guided Design of Selective Inhibitors of Neuronal Nitric Oxide SynthaseSelective Monocationic Inhibitors of Neuronal Nitric Oxide Synthase. Binding Mode Insights from Molecular Dynamics SimulationsPotent and Selective Double-Headed Thiophene-2-carboximidamide Inhibitors of Neuronal Nitric Oxide Synthase for the Treatment of MelanomaAssociation of endothelial nitric oxide synthase gene polymorphisms (894G/T, -786T/C, G10T) and clinical findings in patients with migraineProtective Roles of N-acetyl Cysteine and/or Taurine against Sumatriptan-Induced HepatotoxicityAltered brainstem auditory evoked potentials in a rat central sensitization model are similar to those in migraine.Serotonin, 5HT1 agonists, and migraine: new data, but old questions still not answered.Nutraceuticals and headache: the biological basis.Recurrent headaches may be caused by cerebral toxoplasmosisA novel and potent inhibitor of dimethylarginine dimethylaminohydrolase: a modulator of cardiovascular nitric oxide.Opposite reactivity of meningeal versus cortical microvessels to the nitric oxide donor glyceryl trinitrate evaluated in vivo with two-photon imagingAn Investigation of the Relationship between the eNOS Gene Polymorphism and Diagnosed Migraine.Tumor Necrosis Factor (TNF) -308G>A, Nitric Oxide Synthase 3 (NOS3) +894G>T Polymorphisms and Migraine Risk: A Meta-Analysis.A new small molecule inhibitor of soluble guanylate cyclase.Peripheral endothelial function and arterial stiffness in patients with chronic migraine: a case-control studyTrigeminal Pain Molecules, Allodynia, and Photosensitivity Are Pharmacologically and Genetically Modulated in a Model of Traumatic Brain Injury.Recent advances toward improving the bioavailability of neuronal nitric oxide synthase inhibitors.Characterization of a novel model of chronic migraine.Reduced cGMP levels in CSF of AD patients correlate with severity of dementia and current depression.Pathophysiology of medication overuse headache: insights and hypotheses from preclinical studies.Migraine prophylactic drugs - something new under the sun?Emerging targets in migraine.Drugs targeting nitric oxide synthase for migraine treatment.Emerging drugs for migraine treatment.Part I: Pituitary adenylate cyclase-activating polypeptide-38 induced migraine-like attacks in patients with and without familial aggregation of migraine.The effects of acute and preventive migraine therapies in a mouse model of chronic migraine.The effect of sodium nitroprusside on cerebral hemodynamics and headache in healthy subjects.Nitroglycerin-induced changes in facial skin temperature: 'cold nose' as a predictor of headache?New Agents for Acute Treatment of Migraine: CGRP Receptor Antagonists, iNOS Inhibitors.Soluble guanylyl cyclase is a critical regulator of migraine-associated pain.Ghrelin attenuated hyperalgesia induced by chronic nitroglycerin: CGRP and TRPV1 as targets for migraine management.Ginkgolide B complex efficacy for brief prophylaxis of migraine in school-aged children: an open-label study.Animal Model of Chronic Migraine-Associated Pain.Inducible nitric oxide synthase haplotype associated with migraine and aura.Therapeutic Approaches for the Management of Trigeminal Autonomic Cephalalgias.NXN-188, a selective nNOS inhibitor and a 5-HT1B/1D receptor agonist, inhibits CGRP release in preclinical migraine models
P2860
Q24629739-40927BDE-A149-45D7-A524-67784780F601Q27676660-0F26DE56-863D-416A-9DCB-79A04234277EQ27681378-1327C32E-70AE-4E07-A953-7B9E04F0FB60Q27681413-367CDAE8-8823-4F79-84BB-F109F9EA240DQ28240463-A2EA3709-556B-40CC-ABE1-17826E1CB41FQ28468548-07565BF6-C199-44C8-80D1-7A9CA69B35ECQ30412005-4A49AA1F-4C89-4807-A30B-3A03FB81CB72Q30786129-07D57A3B-6856-4091-A4C1-FEF1543FBF81Q34166931-32FE7548-171E-490F-92C3-E897634BCCECQ34171704-97A85B2E-3AB0-4D05-A1C3-8DA1E1CAA2D0Q35019853-AE6D6C0E-D24F-4EF4-872F-8403D2BB82E6Q35107925-2C1F506D-F237-4CE0-A8E0-A82760F11B7EQ35549655-9043D091-7D29-4B89-96C1-DC8F378EEBFAQ35670677-D3762E92-412E-43E0-8015-536B9554DEFDQ35743176-467504B5-3344-40F7-93DD-E1A3C2D93496Q36749540-70B07D68-8208-4E3E-BA99-C1C9E482A3F7Q36825154-94AC9496-7A91-4F37-B0DF-BA1CEC063118Q37556774-809D2DE3-8F7B-4BBC-A3C0-C758B1B79ABBQ37576753-A409B3EC-FC59-41A2-95C8-807D3DCC1E38Q37689973-B0DA28CD-956E-4055-8C20-0C3B1197AF06Q37858847-554D320C-DF44-4F12-8E45-8AA30FE2CF63Q37912183-A321F2E7-42F0-4EED-9FFC-2660FD6A4BE3Q38169593-139EB4F9-6125-413A-8093-D38EA5E39515Q38211063-0C0167DC-A775-4DE6-AEDE-929D9409E8C5Q38303376-048F783D-0998-45BD-B447-F07B46850F45Q40844180-5028FB46-1DD6-49CA-A12D-14D689AB9725Q41417230-9E2A1458-6996-4A47-9B1B-8ED95D72ACB0Q43549117-05B4B3C8-AC4F-4436-8E85-7BCA81BF0B2EQ45981957-CEC06CF5-82CF-4FAF-A2AB-FE0146D308F5Q46459487-4C4A91CE-2E20-4BC6-A4D8-8B95DFAD6598Q48023073-674DD1B9-9ACA-4AA3-ABDD-6A25DF97DD6DQ48123501-DD9EB58D-86EA-42AD-B086-4D34D2D93499Q51750663-7AA2BDBC-F7C4-433B-86A6-78357DDDBFFCQ53178941-107DCD46-520B-458D-8BE5-3A9A3158E78AQ54330009-C65BBC72-FD5C-4749-8F06-DFF101A1AE9AQ55290441-8C539D61-F513-4AEE-AD16-25FAEC2451DAQ57023928-1D35B8B7-6D46-47B8-9007-F83EFBA26942
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Nitric oxide-related drug targets in headache.
@en
Nitric oxide-related drug targets in headache.
@nl
type
label
Nitric oxide-related drug targets in headache.
@en
Nitric oxide-related drug targets in headache.
@nl
prefLabel
Nitric oxide-related drug targets in headache.
@en
Nitric oxide-related drug targets in headache.
@nl
P2860
P1433
P1476
Nitric oxide-related drug targets in headache.
@en
P2860
P2888
P304
P356
10.1016/J.NURT.2010.03.006
P50
P577
2010-04-01T00:00:00Z
P5875
P6179
1033194220